Overview

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD

Phase:

PHASE1

Details

Lead Sponsor:

Atlas Molecular Pharma

Treatments:

Ciclopirox